BioSpace News Archive

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Ms. Judith Robertson as the Company’s first Chief Commercial Officer, effective 1 January 2022.

Bionomics Limited, a clinical-stage biopharmaceutical company, is pleased to announce that it has initiated its Phase 2 clinical trial to evaluate BNC210 for the acute treatment of Social Anxiety Disorder, with topline results expected by the end of 2022.

Exact Sciences Corp. announced that company management will participate in the following virtual conference and invited investors to participate by webcast.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in investor conferences in January 2022.

Amberstone Biosciences, an emerging biotherapeutics company with unique expertise in conditionally active immunotherapeutics, announced the completion of a $12 million Series A financing round.

Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that a manuscript detailing the results of an analysis of CRP levels from the LIVE-AIR Phase 3 study is available on medRxiv .

Progenity, Inc. today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be available on the conference website beginning at 7 a.m. Eastern / 4 a.m. Pacific on January 10, 2022.

Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies.

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences in the first quarter of 2022.

Immuneering Corporation today announced the appointment of Rimma Steinhertz, Ph.D., PMP to the newly created position of Vice President, Project and Alliance Management, effective immediately.